<DOC>
	<DOCNO>NCT01368107</DOCNO>
	<brief_summary>The purpose study evaluate impact immunotherapy IL-7 CD4 lymphopenia , risk severe haematological toxicity tumor progression metastatic breast cancer patient . The primary objective determine optimal schedule deliver CYT107 chemotherapy base restoration CD4 count . This study phase II , randomise , double-blind , placebo-controlled , single-centre . 24 patient include study .</brief_summary>
	<brief_title>Study Evaluating Impact IL-7 CD4 Lymphopenia , Risks Severe Haematological Toxicity Tumor Progression Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>A key secondary objective determine CYT107 treatment enable reduce incidence severe haematological toxicity ( type haematological toxicity Grade ≥ 3 ) post-chemotherapy . Other secondary objective assess impact CYT107 treatment follow parameter : - Overall incidence side effect ( type grade ) - Progression-free survival ( PFS ) - Compliance chemotherapy regimen ( dose intensity , number chemotherapy cycle ) . - CD4 lymphopenia study period Exploratory biological marker A series biomarkers analyse performed evaluate CYT107 treatment : - selectively stimulate proliferation activation peripheral immune subset ( analysis phenotype activation status peripheral immune e sub-populations ) - selectively improve functional response T cell , DC subsets NK cell . - able revert tolerogenic immune burden increase specific anti-tumor response ( measure antigen specific CD8 response , measure cytokine plasmatic level ) - enable increase TCR diversity ( analysis combinatorial diversity ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphopenia</mesh_term>
	<criteria>Female age 18 year Histologic diagnosis metastatic breast cancer treat capecitabine study entry . NB : Patients previously treat capecitabine eligible 6 month elapse since last capecitabine intake . Lymphopenic ( i.e . least one value lymphocyte count 1500/µL within 15 day Day 0 ) . Performance status ECOG 0 , 1,2 3 Life expectancy ≥ 6months Adequate bone marrow , hepatic renal function follow : Neutrophils ≥ 1,000/µL Platelets ≥ 100 109/µL ASAT , ALAT , Alkaline Phosphatase ≤ 2.5 x ULN Total Bilirubin ≤ 1.5 x ULN INR ≤ 1.5 Calculated creatinin clearance ≥ 60mL/min ( Cockcroft formula MDRD formula patient older 65 year old ) Ability understand sign inform consent Covered medical insurance . Prior history malignancy breast cancer ( except basal cell squamous cell carcinoma skin carcinoma situ cervix ) unless subject free disease least 3 year . No resolution specific toxicity relate prior anticancer therapy Grade ≤2 accord NCI CTCAE v.4.0 ( except lymphopenia , alopecia neuropathy ) Wash period less 5 time halflife previous anticancer treatment study entry , except previous chemotherapy treatment study entry . NB : For patient previously treat hormonotherapy , wash period 1 week sufficient Uncontrolled hypertension ( i.e. , rest systolic blood pressure great than140 mmHg rest diastolic blood pressure great 90 mmHg ) , despite pharmacologic antihypertensive treatment , confirm second blood pressure measurement do later day History lymphoid malignancy ( e.g . Hodgkin disease , non Hodgkin lymphoma , Leukemia ) . History splenectomy hematologic disease associate hypersplenism , gamma betathalassemia , hereditary spherocytosis , Gaucher 's disease , autoimmune hemolytic anemia . Any cardiac , pulmonary , thyroid , renal , hepatic , neurological severe/uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol Any history severe autoimmune disease Hepatitis B antigen ( HBs Ag ) positive , Hepatitis C ( HCV Ab ) antibody positive HCV RNA detectable Documented HIV1 positivity History cardiovascular disorder grade &gt; 2 ( NYHA ) within 6 month precede inclusion Active uncontrolled viral , fungal bacterial infection Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement ( participant must agree refrain substance abuse use entire course study ) Pregnant breastfeed woman No use effective birth control method woman childbearing potential Any contraindication capecitabine treatment ( refer Xeloda SPC Appendix 11 ) anticancer treatment authorize per protocol ( refer respective SPC specific contraindication )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>IL-7</keyword>
	<keyword>metastatic breast cancer patient</keyword>
	<keyword>lymphopenia</keyword>
</DOC>